News about Market

Lupin Expands Specialty Care Business with VISUfarma Buyout

Lupin Limited has announced the completion of its acquisition of VISUfarma B.V. from GHO Capital Partners LLP, marking a significant step in strengthening its specialty care portfolio and expanding its footprint in Europe.

Market | 02/04/2026 | By Darshana

European Commission Approves Needle-Free Adrenaline Nasal Spray for Children with Severe Allergies

ALK’s EURneffy 1 mg expands access to needle-free emergency treatment for anaphylaxis in children aged 4 and above across the EU.

Market | 02/04/2026 | By News Bureau

Gilead Extends Tender Offer to Acquire Arcellx

Gilead extends tender offer to acquire Arcellx until April 24, 2026, providing additional time for shareholders to participate in the proposed acquisition.

Market | 02/04/2026 | By News Bureau |  123

GHIT Fund and TSRI Sign MoU to Boost Global Infectious Disease R&D Collaboration

The partnership aims to co-fund research on malaria, tuberculosis, and neglected tropical diseases while strengthening innovation ecosystems and capacity building across Thailand and Japan.

Market | 01/04/2026 | By News Bureau

Semarion Raises USD 3.8 Million to Scale Cell Assay Technology and Accelerate Pharma Adoption

Semarion raises USD 3.8 million to expand manufacturing and scale its SemaCyte microcarrier platform for pharmaceutical use.

Market | 01/04/2026 | By News Bureau

EU Grants Conditional Approval to Rezurock for Chronic GVHD Treatment

European Commission authorises belumosudil for patients aged 12 plus with limited treatment options, marking a significant advance in managing a life-threatening post-transplant condition.

Market | 01/04/2026 | By News Bureau

Freudenberg Reports INR 4,427 Crore Sales, Emerges as Key Growth Driver

Freudenberg reports €11.73B in sales and €1.09B operating profit, highlighting strong financial performance with continued investments in R&D and AI-driven innovation with an investment of €200 million by 2028.

Market | 01/04/2026 | By News Bureau |  113

Biogen to Acquire Apellis, Expands Immunology and Rare Disease Portfolio

Biogen to acquire Apellis for USD 5.6 billion, adding EMPAVELI and SYFOVRE to expand its immunology, rare disease and nephrology portfolio and drive long-term growth.

Market | 01/04/2026 | By News Bureau

Meiji Seika Pharma Invests in Centivax for Universal Vaccine Platform

Meiji Seika Pharma invests in Centivax to advance a next-generation universal vaccine platform, with lead candidate Centi-Flu 01 currently in a Phase 1 influenza study.

Market | 31/03/2026 | By News Bureau

Biocytogen Grants Licence for RenNano Platform to Taisho Pharmaceutical

Biocytogen licenses its RenNano platform to Taisho Pharmaceutical to advance fully human heavy chain-only antibody discovery, supporting in-vivo screening and downstream research.

Market | 31/03/2026 | By News Bureau